Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China.

MLA

Wan, Yuansheng, et al. “Methodology and Results of Cost-Effectiveness of LDL-C Lowering with Evolocumab in Patients with Acute Myocardial Infarction in China.” Cost Effectiveness & Resource Allocation, vol. 21, no. 1, Dec. 2023, pp. 1–15. EBSCOhost, https://doi.org/10.1186/s12962-023-00501-4.

APA

Wan, Y., Liu, J., Zhan, X., Zhang, Y., & You, R. (2023). Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China. Cost Effectiveness & Resource Allocation, 21(1), 1–15. https://doi.org/10.1186/s12962-023-00501-4

Chicago

Wan, Yuansheng, Jinyu Liu, Xiaolian Zhan, Yu Zhang, and Ruxu You. 2023. “Methodology and Results of Cost-Effectiveness of LDL-C Lowering with Evolocumab in Patients with Acute Myocardial Infarction in China.” Cost Effectiveness & Resource Allocation 21 (1): 1–15. doi:10.1186/s12962-023-00501-4.